ENvue Medical

Company Overview

Snapshot

Founded in December 2003, ENvue Medical operates with 11–50 employees and has raised a total of $24.5 million across 9 funding rounds. The company went public on NASDAQ in April 2014, marking a significant milestone in its journey to redefine clinical navigation.

Business overview

ENvue Medical is a Health Tech & Life Sciences company focused on redefining clinical navigation through its Enhanced Navigation platform. The company develops technology to support critical procedures such as enteral feeding and vascular access, aiming to reduce complications, accelerate training, and improve efficiency. Its core products include WoundShield, UroShield, and PainShield, serving hospitals and clinicians in markets across North America, Europe, East Asia, and Southeast Asia.

Strategic signal

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a major U.S. Group Purchasing Organization (GPO) for a health system operating over 90 hospitals. This renewal, alongside another three-year contract renewal at a 12-hospital U.S. health network, indicates strong market adoption and validates the ENvue Navigation Platform as a standard of care, signaling robust commercial momentum and continued revenue opportunities for investors.

Company Intelligence Q&A

What was a key recent development regarding ENvue Medical's intellectual property?

In May 2026, ENvue Medical added to its intellectual property portfolio by securing a USPTO Notice of Allowance for ultrasound-enhanced cannabinoid drug delivery technology.

What significant commercial agreements did ENvue Medical secure in May 2026?

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a GPO for one of the largest health systems in the U.S., operating over 90 hospitals. Additionally, the company secured a three-year contract renewal at a 12-hospital U.S. health network, establishing the ENvue Navigation Platform as a standard of care.

What was a notable product launch by NanoVibronix (now ENvue Medical) in September 2025?

In September 2025, NanoVibronix launched "Oscar" Training Aid to accelerate ENvue adoption and unlock new revenue opportunities.

What patent was granted to NanoVibronix (now ENvue Medical) in September 2025?

In September 2025, NanoVibronix announced a U.S. patent granted to ENvue Medical for real-time imaging overlay in navigation technology.

What was the outcome of the public offering in May 2025?

In May 2025, NanoVibronix announced the closing of a $10 million public offering of preferred stock and warrants.